Literature DB >> 10420156

Caveolin expression is decreased following androgen deprivation in human prostate cancer cell lines.

B R Pflug1, R E Reiter, J B Nelson.   

Abstract

BACKGROUND: Increased expression of caveolin has been associated with prostate cancer progression. In a mouse reconstitution model of prostate cancer, expression of caveolin was inversely related to androgen sensitivity: androgen independent clones had high caveolin expression; low caveolin expression was associated with sensitivity to androgen withdrawal. In contrast, several independent observations support the hypothesis that caveolin functions as a tumor suppressor.
METHODS: Caveolin expression was studied by Western blot analysis and/or immunohistochemistry in three androgen-sensitive human prostate cancer cell lines LNCaP, LAPC-4 and LAPC-9, and following acute and chronic androgen deprivation, and in benign prostate epithelial cells. Expression of caveolin, androgen receptor (AR) and prostate specific antigen (PSA) was also examined after reintroduction of androgen.
RESULTS: LNCaP grown continuously under androgen-depleted conditions for 6 to 42 months produced several androgen-independent and tumorigenic clones: tumors formed in 13/15 castrate and 7/15 intact male athymic nu/nu mice, but no tumors formed in wildtype LNCaP-bearing animals. Caveolin expression was decreased in every androgen-deprived LNCaP clone and following 150 days of androgen deprivation in LAPC-4. Caveolin expression by LAPC-9 was very low. Following exposure to dihydrotestosterone in vitro, caveolin and PSA expression increased within three days in the androgen-deprived clones of LNCaP. Benign prostate epithelial cells have high caveolin expression.
CONCLUSIONS: Unlike the mouse reconstitution model of prostate cancer, the pattern of caveolin expression in benign prostatic epithelium and androgen-sensitive human prostate cancer is consistent with tumor suppressive activity. Copyright 1999 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10420156     DOI: 10.1002/(sici)1097-0045(19990901)40:4<269::aid-pros9>3.0.co;2-6

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  18 in total

1.  Correlation of Sprouty1 and Jagged1 with aggressive prostate cancer cells with different sensitivities to androgen deprivation.

Authors:  Naoki Terada; Takumi Shiraishi; Yu Zeng; Koh-Meng Aw-Yong; Steven M Mooney; Zhi Liu; Sayuri Takahashi; Jun Luo; Shawn E Lupold; Prakash Kulkarni; Robert H Getzenberg
Journal:  J Cell Biochem       Date:  2014-09       Impact factor: 4.429

2.  The cancer/testis antigen prostate-associated gene 4 (PAGE4) is a highly intrinsically disordered protein.

Authors:  Yu Zeng; Yanan He; Fan Yang; Steven M Mooney; Robert H Getzenberg; John Orban; Prakash Kulkarni
Journal:  J Biol Chem       Date:  2011-02-25       Impact factor: 5.157

3.  Resistance to paclitaxel increases the sensitivity to other microenvironmental stresses in prostate cancer cells.

Authors:  Youqiang Li; Yu Zeng; Steven M Mooney; Bo Yin; Atsushi Mizokami; Mikio Namiki; Robert H Getzenberg
Journal:  J Cell Biochem       Date:  2011-08       Impact factor: 4.429

4.  G-protein alpha-s and -12 subunits are involved in androgen-stimulated PI3K activation and androgen receptor transactivation in prostate cancer cells.

Authors:  Jianjun Liu; Hyewon Youn; Jun Yang; Ningchao Du; Jihong Liu; Hongwei Liu; Benyi Li
Journal:  Prostate       Date:  2011-02-09       Impact factor: 4.104

5.  Phenotypic characterization of two novel cell line models of castration-resistant prostate cancer.

Authors:  Michael C Haffner; Akshay Bhamidipati; Harrison K Tsai; David M Esopi; Ajay M Vaghasia; Jin-Yih Low; Radhika A Patel; Gunes Guner; Minh-Tam Pham; Nicole Castagna; Jessica Hicks; Nicolas Wyhs; Ruedi Aebersold; Angelo M De Marzo; William G Nelson; Tiannan Guo; Srinivasan Yegnasubramanian
Journal:  Prostate       Date:  2021-08-16       Impact factor: 4.104

6.  Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia.

Authors:  Hyangkyu Lee; David S Park; Babak Razani; Robert G Russell; Richard G Pestell; Michael P Lisanti
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

7.  Xenoestrogen interference with nongenomic signaling actions of physiological estrogens in endocrine cancer cells.

Authors:  Cheryl S Watson; Luke Koong; Yow-Jiun Jeng; Rene Vinas
Journal:  Steroids       Date:  2018-07-20       Impact factor: 2.668

8.  Knockdown of caveolin-1 by siRNA inhibits the transformation of mouse hepatoma H22 cells in vitro and in vivo.

Authors:  Shujing Wang; Li Jia; Huimin Zhou; Wei Shi; Jianing Zhang
Journal:  Oligonucleotides       Date:  2009-03

9.  Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer.

Authors:  Oliver C Rogers; Lizamma Antony; Oren Levy; Nitin Joshi; Brian W Simons; Susan L Dalrymple; D Marc Rosen; Andrew Pickering; Haoyue Lan; Heidi Kuang; Sudhir H Ranganath; Lei Zheng; Jeffrey M Karp; S Peter Howard; Samuel R Denmeade; John T Isaacs; W Nathaniel Brennen
Journal:  Mol Cancer Ther       Date:  2020-09-17       Impact factor: 6.261

10.  Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.

Authors:  W Nathaniel Brennen; Yezi Zhu; Ilsa M Coleman; Susan L Dalrymple; Lizamma Antony; Radhika A Patel; Brian Hanratty; Roshan Chikarmane; Alan K Meeker; S Lilly Zheng; Jody E Hooper; Jun Luo; Angelo M De Marzo; Eva Corey; Jianfeng Xu; Srinivasan Yegnasubramanian; Michael C Haffner; Peter S Nelson; William G Nelson; William B Isaacs; John T Isaacs
Journal:  JCI Insight       Date:  2021-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.